Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Atherosclerosis Clinical Trials

11 recruiting trials for Atherosclerosis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 3NCT05476991

Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to...

REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 28001 location
RECRUITINGNCT06694012

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and...

Sponsor: Osaka Metropolitan UniversityEnrolling: 20001 location
RECRUITINGNCT04511247

SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal...

Sponsor: Concept Medical Inc.Enrolling: 21920 locations
RECRUITINGNCT04511234

Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal...

Sponsor: Concept Medical Inc.Enrolling: 27920 locations
RECRUITINGNCT06519292

Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related...

Sponsor: Hanneke W. M. van LaarhovenEnrolling: 2141 location
RECRUITINGPhase 4NCT05365425

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.

Sponsor: Seoul National University Bundang HospitalEnrolling: 561 location
RECRUITINGNCT05325034

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific

Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study. Patients will be recruited during hospitalisation and be...

Sponsor: Stephen NichollsEnrolling: 200020 locations
RECRUITINGPhase 2NCT06488105

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association...

Sponsor: Wake Forest University Health SciencesEnrolling: 1301 location
RECRUITINGNCT00353782

Causes and Natural History of Dyslipidemias

This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the...

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)Enrolling: 20001 location
RECRUITINGNCT04073797

PET Imaging of Inflammation and Lipid Lowering Study

While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as...

Sponsor: University of CambridgeEnrolling: 631 location
RECRUITINGNCT05642858

Text Education About Cardiovascular Health and HIV (TEACH-HIV)

The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).

Sponsor: University of California, San FranciscoEnrolling: 2602 locations